Mediwhale has announced that its retinal AI tool, Dr. Noon, has received CE MDR certification, allowing it to be marketed across the European Union.
This certification aligns with the EU's Medical Device Regulation, which was established to enhance product safety and effectiveness in the medical device sector. Dr. Noon leverages AI to analyze retinal images, aiding in the diagnosis of eye diseases while also predicting cardiovascular risks with a level of precision comparable to cardiac CT scans. The tool combines two existing products in Korea, offering a comprehensive solution for both ophthalmic diagnostics and cardiovascular risk assessment.
The significance of this certification is underscored by its focus on predictive capabilities, a relatively rare achievement within the stringent CE MDR framework. This highlights Mediwhale's innovative approach in a market that has primarily concentrated on diagnostic functions. The approval not only strengthens Dr. Noon’s position in Europe but also enhances the company's credibility with healthcare providers and potential partners globally.
Mediwhale’s CEO emphasized the milestone's importance, noting that it validates their unique strategy of assessing systemic disease risks through retinal analysis. The company is also pursuing FDA approval for Dr. Noon in the U.S. and has plans for future products, including a solution for chronic kidney disease. As Mediwhale continues its global expansion efforts, the CE MDR certification is expected to facilitate its market growth and partnerships.